These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 32237290)

  • 21. A phase 1, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and pharmacokinetics of single and multiple doses of lisdexamfetamine dimesylate in Japanese and Caucasian healthy adult subjects.
    Ermer J; Martin P; Corcoran M; Matsuo Y
    Neuropsychopharmacol Rep; 2020 Mar; 40(1):16-29. PubMed ID: 31765110
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Binge-Eating Disorder in Adults: A Systematic Review and Meta-analysis.
    Brownley KA; Berkman ND; Peat CM; Lohr KN; Cullen KE; Bann CM; Bulik CM
    Ann Intern Med; 2016 Sep; 165(6):409-20. PubMed ID: 27367316
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A psychometric analysis and revalidation of the Yale-Brown Obsessive Compulsive Scale modified for Binge Eating in adults with binge eating disorder.
    Yee K; Serrano D; Kando J; McElroy SL
    Qual Life Res; 2019 Dec; 28(12):3385-3394. PubMed ID: 31473907
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lisdexamfetamine Dimesylate Effects on Binge Eating Behaviour and Obsessive-Compulsive and Impulsive Features in Adults with Binge Eating Disorder.
    McElroy SL; Mitchell JE; Wilfley D; Gasior M; Ferreira-Cornwell MC; McKay M; Wang J; Whitaker T; Hudson JI
    Eur Eat Disord Rev; 2016 May; 24(3):223-31. PubMed ID: 26621156
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Double-blind, placebo-controlled study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder.
    Adler LA; Goodman DW; Kollins SH; Weisler RH; Krishnan S; Zhang Y; Biederman J;
    J Clin Psychiatry; 2008 Sep; 69(9):1364-73. PubMed ID: 19012818
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adjunctive lisdexamfetamine dimesylate therapy in adult outpatients with predominant negative symptoms of schizophrenia: open-label and randomized-withdrawal phases.
    Lasser RA; Dirks B; Nasrallah H; Kirsch C; Gao J; Pucci ML; Knesevich MA; Lindenmayer JP
    Neuropsychopharmacology; 2013 Oct; 38(11):2140-9. PubMed ID: 23756608
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Relationships between clinical scales and binge eating days in adults with moderate to severe binge eating disorder in two Phase III studies.
    Citrome L; Kando JC; Bliss C
    Neuropsychiatr Dis Treat; 2018; 14():537-546. PubMed ID: 29497297
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lisdexamfetamine suppresses instrumental and consummatory behaviors supported by foods with varying degrees of palatability: Exploration of a binge-like eating model.
    Presby RE; Rotolo RA; Yang JH; Correa M; Salamone JD
    Pharmacol Biochem Behav; 2020 Feb; 189():172851. PubMed ID: 31931017
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Randomized, double-blind, placebo-controlled, crossover study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder: novel findings using a simulated adult workplace environment design.
    Wigal T; Brams M; Gasior M; Gao J; Squires L; Giblin J;
    Behav Brain Funct; 2010 Jun; 6():34. PubMed ID: 20576091
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lisdexamfetamine in Pediatric Binge Eating Disorder: A Retrospective Chart Review.
    Guerdjikova AI; Blom TJ; Mori N; Matthews A; Cummings T; Casuto LL; McElroy SL
    Clin Neuropharmacol; 2019; 42(6):214-216. PubMed ID: 31725476
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder previously treated with amphetamines: analyses from a randomized, double-blind, multicenter, placebo-controlled titration study.
    Babcock T; Dirks B; Adeyi B; Scheckner B
    BMC Pharmacol Toxicol; 2012 Dec; 13():18. PubMed ID: 23254273
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Trial protocol of an open label pilot study of lisdexamfetamine for the treatment of acute methamphetamine withdrawal.
    Acheson LS; Ezard N; Lintzeris N; Dunlop A; Brett J; Rodgers C; Gill A; Christmass M; McKetin R; Farrell M; Shoptaw S; Siefried KJ
    PLoS One; 2022; 17(10):e0275371. PubMed ID: 36190973
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Study protocol: a dose-escalating, phase-2 study of oral lisdexamfetamine in adults with methamphetamine dependence.
    Ezard N; Dunlop A; Clifford B; Bruno R; Carr A; Bissaker A; Lintzeris N
    BMC Psychiatry; 2016 Dec; 16(1):428. PubMed ID: 27905916
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical response and symptomatic remission in short- and long-term trials of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder.
    Mattingly GW; Weisler RH; Young J; Adeyi B; Dirks B; Babcock T; Lasser R; Scheckner B; Goodman DW
    BMC Psychiatry; 2013 Jan; 13():39. PubMed ID: 23356790
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A post hoc comparison of the effects of lisdexamfetamine dimesylate and osmotic-release oral system methylphenidate on symptoms of attention-deficit hyperactivity disorder in children and adolescents.
    Soutullo C; Banaschewski T; Lecendreux M; Johnson M; Zuddas A; Anderson C; Civil R; Higgins N; Bloomfield R; Squires LA; Coghill DR
    CNS Drugs; 2013 Sep; 27(9):743-51. PubMed ID: 23801529
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy, safety, and tolerability of nivasorexant in adults with binge-eating disorder: A randomized, Phase II proof of concept trial.
    McElroy SL; Coloma PM; Berger B; Guerdjikova AI; Joyce JM; Liebowitz MR; Pain S; Rabasa C
    Int J Eat Disord; 2023 Nov; 56(11):2120-2130. PubMed ID: 37584285
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Attention deficit hyperactivity disorder subtypes and symptom response in adults treated with lisdexamfetamine dimesylate.
    Mattingly G; Weisler R; Dirks B; Babcock T; Adeyi B; Scheckner B; Lasser R
    Innov Clin Neurosci; 2012 May; 9(5-6):22-30. PubMed ID: 22808446
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Relationship of ADHD symptoms and global illness severity in adults treated with lisdexamfetamine dimesylate.
    Weisler RH; Babcock T; Adeyi B; Brams M
    Postgrad Med; 2014 Sep; 126(5):31-41. PubMed ID: 25295648
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Maintenance of efficacy of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder: randomized-withdrawal study design.
    Coghill DR; Banaschewski T; Lecendreux M; Johnson M; Zuddas A; Anderson CS; Civil R; Dauphin M; Higgins N; Lyne A; Gasior M; Squires LA
    J Am Acad Child Adolesc Psychiatry; 2014 Jun; 53(6):647-657.e1. PubMed ID: 24839883
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.